Market Cap 498.43M
Revenue (ttm) 0.00
Net Income (ttm) -98.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,077,901
Avg Vol 949,694
Day's Range N/A - N/A
Shares Out 54.00M
Stochastic %K 62%
Beta 1.66
Analysts Strong Sell
Price Target $19.22

Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 547 9879
Address:
345 Park Avenue South, 6th Floor, New York, United States
JarvisFlow
JarvisFlow Oct. 21 at 11:11 AM
HC Wainwright & Co. updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 15 → 13.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 17 at 10:56 AM
$LXEO Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00
0 · Reply
DonCorleone77
DonCorleone77 Oct. 16 at 8:34 PM
$LXEO Lexeo announces common stock and warrants offering, no amount given
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 2:26 PM
Guggenheim updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 30.
0 · Reply
Cinoooo
Cinoooo Oct. 15 at 12:45 PM
$LXEO okay we got a PT of 30 and hit 8.99 PM blast us thru 9 today and let’s hit double digits.
0 · Reply
Cinoooo
Cinoooo Oct. 15 at 1:29 AM
$LXEO one share sold dropped it 2%. Sitting on the sideline watching everything run 20% up got me like
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 10 at 5:05 PM
Therapeutics Company Advances Gene Therapy Breakthrough https://ow.ly/7Vgj50X9Wbc In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. ($LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 9 at 5:24 PM
Biotech Firm Uncovers Breakthrough Gene Therapy in New York https://ow.ly/uQAf50X9kNq Lexeo Therapeutics Inc. ($LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades.
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 9 at 5:08 PM
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease https://ow.ly/gYQz50X9kmb Lexeo Therapeutics Inc. ($LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
0 · Reply
nbkihy8
nbkihy8 Oct. 8 at 3:53 PM
$LXEO I have a feeling they push this green today
0 · Reply
Latest News on LXEO
Lexeo Therapeutics, Inc. - Special Call

Oct 7, 2025, 12:45 PM EDT - 20 days ago

Lexeo Therapeutics, Inc. - Special Call


Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 12:05 PM EDT - 1 year ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet


Lexeo Therapeutics Proposes Terms For $126 Million IPO

Oct 31, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Proposes Terms For $126 Million IPO


Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Oct 2, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort


JarvisFlow
JarvisFlow Oct. 21 at 11:11 AM
HC Wainwright & Co. updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 15 → 13.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 17 at 10:56 AM
$LXEO Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00
0 · Reply
DonCorleone77
DonCorleone77 Oct. 16 at 8:34 PM
$LXEO Lexeo announces common stock and warrants offering, no amount given
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 2:26 PM
Guggenheim updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 30.
0 · Reply
Cinoooo
Cinoooo Oct. 15 at 12:45 PM
$LXEO okay we got a PT of 30 and hit 8.99 PM blast us thru 9 today and let’s hit double digits.
0 · Reply
Cinoooo
Cinoooo Oct. 15 at 1:29 AM
$LXEO one share sold dropped it 2%. Sitting on the sideline watching everything run 20% up got me like
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 10 at 5:05 PM
Therapeutics Company Advances Gene Therapy Breakthrough https://ow.ly/7Vgj50X9Wbc In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. ($LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 9 at 5:24 PM
Biotech Firm Uncovers Breakthrough Gene Therapy in New York https://ow.ly/uQAf50X9kNq Lexeo Therapeutics Inc. ($LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades.
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 9 at 5:08 PM
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease https://ow.ly/gYQz50X9kmb Lexeo Therapeutics Inc. ($LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
0 · Reply
nbkihy8
nbkihy8 Oct. 8 at 3:53 PM
$LXEO I have a feeling they push this green today
0 · Reply
ZenfireTrading
ZenfireTrading Oct. 8 at 1:33 PM
$LXEO Sometimes you only take what you can get! And this is a prime example of it. If you want to see the long/short quant side of the market, visit zenfiretrading.com/join ⚡✨
0 · Reply
boncuk
boncuk Oct. 8 at 12:38 PM
$BJDX $PCSA $TMQ $LXEO thank u for alerts ...
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 9:31 AM
HC Wainwright & Co. has updated their rating for Lexeo Therapeutics ( $LXEO ) to Buy with a price target of 15.
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 8 at 4:11 AM
Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In $LXEO https://stocktwits.com/news/equity/markets/lexeo-therapeutics-stock-hits-11-month-high-on-bullish-analyst-calls-for-friedreich-s-ataxia-gene-therapy/ch6E3ylR3L3
0 · Reply
Prosperity_Trades
Prosperity_Trades Oct. 7 at 11:55 PM
$TMQ Play of the day with $CISS $GLTO $LXEO
1 · Reply
DayTrade_4Life
DayTrade_4Life Oct. 7 at 9:37 PM
Today's results from the Watchlist and Alerts. See profile for more info and join us. GLTO: $12 to 36.25 (202%) Alert BQ: $22.05 to 46.70 (111%) Weekly Watchlist PRHI: 1.40 to 2.83 (102%); $2 breakout (41%) WL SPRB: $225 to $383 (70%) WL BURU: .30 to .49 (63%) Alert $BJDX: 1.76 to 3.06 (73%); $2 breakout (53%) WL $PCSA: .35 to .44 (25%) WL $TMQ: 5.50 to 7.98 (45%); 7.05 breakout (13%) WL $LXEO: $9 to $10.02 (11%) Alert
1 · Reply
GuyFawkes_EOD
GuyFawkes_EOD Oct. 7 at 8:37 PM
$LXEO They sure got the SP pinned 🤔
0 · Reply
RunnerSignals
RunnerSignals Oct. 7 at 8:35 PM
Top Gainers: $TMQ $LXEO $BURU Top Losers: $AEHR $HUMA Full Story here... https://stocksrunner.com/news/2025-10-07-top-movers-and-shakers-shake-markets
0 · Reply
Hernandrod12
Hernandrod12 Oct. 7 at 8:24 PM
0 · Reply
nevermind889
nevermind889 Oct. 7 at 8:03 PM
$APLT Solid finish and nice AH. Great volume! Day #3 above 1$. Hoping to follow in $DVLT footstep and hit 2.5$ very soon! $LXEO $RVPH
0 · Reply
anachartanalyst
anachartanalyst Oct. 7 at 7:03 PM
$LXEO https://anachart.com/wp-content/uploads/ana_temp/1759863767_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 5:56 PM
Chardan Capital has updated their rating for Lexeo Therapeutics ( $LXEO ) to Buy with a price target of 17.
0 · Reply